Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM185PE | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7532.091 | 1.0775 | 1.1651 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7532.091 | 1.0833 | 1.1775 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7532.091 | 1.0311 | 1.0662 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7532.091 | 1.0088 | 1.0186 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 7532.091 | 1.0554 | 1.1179 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 7532.091 | 1.0346 | 1.0736 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 7532.091 | 0.9995 | 0.9989 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 7532.091 | 0.9047 | 0.7982 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 7532.091 | 0.8261 | 0.6327 | 0.9414 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7533.091 | 1.0453 | 1.1210 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7533.091 | 1.0640 | 1.1714 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7533.091 | 0.9627 | 0.9017 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7533.091 | 1.0183 | 1.0486 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.107 | uM | 7533.091 | 1.0070 | 1.0185 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.533 | uM | 7533.091 | 1.0201 | 1.0535 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 2.67 | uM | 7533.091 | 0.9630 | 0.9025 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 13.3 | uM | 7533.091 | 0.8917 | 0.7183 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 66.7 | uM | 7533.091 | 0.5369 | -0.1228 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7534.091 | 1.1219 | 1.2464 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7534.091 | 0.9855 | 0.9706 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7534.091 | 1.0418 | 1.0844 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7534.091 | 0.9985 | 0.9970 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.107 | uM | 7534.091 | 1.0364 | 1.0736 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.533 | uM | 7534.091 | 1.0065 | 1.0132 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 2.67 | uM | 7534.091 | 0.8629 | 0.7232 | 0.9898 |